Clinical Trials Logo

Carcinoma, Endometrioid clinical trials

View clinical trials related to Carcinoma, Endometrioid.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06468215 Not yet recruiting - Clinical trials for Fertility Preservation

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Start date: July 2024
Phase: N/A
Study type: Interventional

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

NCT ID: NCT06466382 Not yet recruiting - Clinical trials for Fallopian Tube Neoplasms

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

OVPrecision
Start date: September 2024
Phase: N/A
Study type: Interventional

The long-term goal of this research project is to demonstrate whether HRD negative (HPR) patients benefit when additional multimodal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

NCT ID: NCT06393751 Not yet recruiting - Clinical trials for Recurrent Platinum-Resistant Ovarian Carcinoma

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Start date: June 21, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.